Monthly archives for December, 2022
| Indoco Remedies is an attractive investment proposition. Buy for target price of Rs 469 (24% upside): SMIFS | |
| Company: | indoco remedies |
| Brokerage: | SMIFS |
| Date of report: | December 23, 2022 |
| Type of Report: | Initiating Coverage |
| Recommendation: | Buy |
| Upside Potential: | 24% |
| Summary: | Strong business fundamentals such as diversified segments mix and strong product portfolio along with high return ratios make Indoco an attractive investment proposition |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | indoco remedies, SMIFS |
| New Year Outlook & Top Picks – 2023 by Motilal Oswal | |
| Company: | Model Portfolio |
| Brokerage: | Motilal Oswal |
| Date of report: | December 22, 2022 |
| Type of Report: | Model Portfolio |
| Recommendation: | Buy |
| Upside Potential: | 100% |
| Summary: | India stands out like an oasis in the desert, where rest of world is facing multiple challenges. Domestic flows too have remained strong and now FIIs have turned buyers. Nifty now trades at a 1 year forward P/E of 20x, which seems fair, in our view. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Model Portfolio, Motilal Oswal |
| Risk reward still favours PSU bank valuations. Top 3 Stock Picks By ICICI Direct | |
| Company: | Model Portfolio, PSU Banks |
| Brokerage: | ICICI-Direct |
| Date of report: | December 22, 2022 |
| Type of Report: | Sector Report |
| Recommendation: | Buy |
| Upside Potential: | 27% |
| Summary: | A stellar run up by PSU banks had all eyes glued towards them. We tried to analyse the factors leading to the rally and what is in store ahead |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | ICICI-Direct, Model Portfolio, PSU, PSU Banks |
| Top 4 Chemical Stock Picks By Nirmal Bang | |
| Company: | Specialty Chemicals |
| Brokerage: | Nirmal Bang |
| Date of report: | December 21, 2022 |
| Type of Report: | Sector Report |
| Recommendation: | Buy |
| Upside Potential: | 100% |
| Summary: | We are positive on the CSM leader PI Industries and CPC companies UPL and Sumitomo Chemical India (SCIL), with new product launches, pricing power and long runway for growth. Potential catalysts are a likely PLI scheme for Agrochemicals and concessions related to tariff restructuring to support value addition CPC. Key ‘BUYs’ are PI Industries and UPL in large caps and SCIL in midcaps- on dips. Coromandel International (CRIN) is a value Buy |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Best Agro Chemicals stocks to buy, Nirmal Bang |
| Taxfree & Taxable bonds Retail NCD Reckoner by HDFC Securities | |
| Company: | Taxfree & Taxable bonds Retail NCD Reckoner |
| Brokerage: | HDFC Sec |
| Date of report: | December 16, 2022 |
| Type of Report: | Techno-Funda |
| Recommendation: | Buy |
| Upside Potential: | 9.27% |
| Summary: | In Tax Free Bonds, to avail (or retain) the 25bps additional in the coupon rate, Investors should be aware that the total investment in the aggregate face value of Bonds held by the Bondholders in all the Series of Bonds, allotted under the relevant Tranche Issue shall be clubbed and taken together and that should be up to Rs. 10 Lakhs |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Taxfree & Taxable bonds Retail NCD Reckoner |
| Top 9 Techno-Funda Stock Picks for CY23 by ICICI Direct | |
| Company: | Model Portfolio |
| Brokerage: | ICICI-Direct |
| Date of report: | December 20, 2022 |
| Type of Report: | Model Portfolio |
| Recommendation: | Buy |
| Upside Potential: | 100% |
| Summary: | History does not repeat but it rhymes: Indian equities are likely to display the same rhythm that the US and Nikkei did in 1990-2000 and 1980-1990, respectively, i.e. delivering a decadal move of 5x on headline indices. Our prognosis of various Technical studies leads us to the conclusion that the Nifty is poised to reach towards 50000 by CY30. More so, the performance of 2021 and 2022 further adds strength to our argument given the Nifty is mimicking our forecast trajectory. What is more exciting is that we are entering 2023, which, as per decadal studies, has turned out to be a strong year |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | ICICI-Direct, Model Portfolio |
| GAIL’s Valuations remain overly pessimistic and ignore the solid business model and strong long-term prospects: ICICI Securities | |
| Company: | GAIL |
| Brokerage: | ICICI Securities |
| Date of report: | December 20, 2022 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 30% |
| Summary: | We value GAIL on the basis of FY24E EV/EBITDA multiples of 4-5.5x applied to various segments, leading to a target price of Rs127/sh (implying 30% upside). Current valuations of 6.3x FY24E EPS and 5.3x FY24E EV/EBITDA remain well below 5-year valuation bands. Even at our target price, P/E of 8.2x FY24E EPS, and |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | GAIL, ICICI Securities |
| Indian Hotels is rapid scaling up margin-accretive new businesses. Buy for target price of Rs 390: Motilal Oswal | |
| Company: | Indian Hotels |
| Brokerage: | Motilal Oswal |
| Date of report: | December 19, 2022 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 19% |
| Summary: | Indian Hotel’s (IH’s) new and re-imagined businesses Ama Stays, Qmin, Chambers, and Management contracts are expected to scale up rapidly on the lower base and high growth runway. These businesses are margin accretive with higher margin flowthrough, thereby driving up the RoCE. The new business is expected to contribute ~26% to the company’s operating profits by FY25. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Indian Hotels, Motilal Oswal |
| JB Chemicals is the preferred pick in the Pharma sector: Nirmal Bang | |
| Company: | JB Chem |
| Brokerage: | Nirmal Bang |
| Date of report: | December 18, 2022 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 15.2% |
| Summary: | JB Chem has 7 formulations facilities and 1 API facility with most of the units approved by all major compliance agencies, including units TI10 (OSD), T20 (OSD) and D9 (API), which are USFDA compliant as well. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | JB Chem, Nirmal Bang |
| PCBL Ltd is a carbon black giant, set to grow at a fast clip. Buy for 35% upside: SMIFS | |
| Company: | PCBL |
| Brokerage: | SMIFS |
| Date of report: | December 18, 2022 |
| Type of Report: | Initiating Coverage |
| Recommendation: | Buy |
| Upside Potential: | 35% |
| Summary: | Currently, the stock is trading at inexpensive valuation on FY25E P/E of ~9.3x. We value the stock on forward P/E multiple of 12.5x owing to increasing share of speciality business, robust volume growth & rising exports share and, thereby, arrive at target price of Rs 183 per share which offers upside of 35% from current valuations. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | PCBL, SMIFS |